NEUROSCIENTIFIC BIOPHARMACEU

Neuroscientific Biopharmaceu Surges on Tax Refund, Eyes Stroke & Dementia Breakthroughs

Neuroscientific Biopharmaceu (NSB.AX) gains cash‑positive momentum and targets stroke & dementia breakthroughs—investors eye a potential rebound from 52‑week lows.

NEUROSCIENTIFIC BIOPHARMACEU
Australia
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Samantha Roth

23/10/2026, 11:46

3 minutes to read

NSB.AX Surges 3.45% Amid Positive Pipeline News & Institutional Buying Momentum

NSB.AX rises 3.45% to AUD 0.06 amid growing institutional interest and upcoming Phase II trials, positioning the company for a potential trend shift above its 200‑day SMA.

NEUROSCIENTIFIC BIOPHARMACEU
Australia
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Samantha Roth

22/10/2026, 18:26

3 minutes to read